Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rybelsus
Pharma
Novo reports 2 trial failures for GLP-1 in Alzheimer's disease
Novo's share price dropped in reaction to the company coming up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease.
Kevin Dunleavy
Nov 24, 2025 11:41am
Novo's Rybelsus gains FDA expansion to reduce risk of MACE
Oct 21, 2025 10:45am
Novo Nordisk applies for FDA approval of semaglutide obesity pill
Apr 22, 2025 8:50am
Novo's oral GLP-1 Rybelsus cuts heart disease risks
Mar 31, 2025 11:30am
Novo, Lilly poised to overcome GLP-1 supply constraints in 2025
Dec 30, 2024 8:00am
Novo’s chief scientific officer looks to the future of GLP-1s
Dec 13, 2024 8:50am
